肺高血圧症Q&A

出版社： 先端医学社
著者：
発行日： 2015-10-01
分野： 臨床医学：内科  >  呼吸器一般
ISBN： 9784865501186
電子書籍版： 2015-10-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,840 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,420 円(税込)

購入する

商品紹介

かつて、肺高血圧症は有効な治療法がなく、きわめて予後不良な疾患であった。しかし、病態の解明とともに治療薬の開発が進み、予後改善が期待されるようになった。一方、治療の遅れは生命予後に数年以上の差を生み出すこともわかり、その早期診断・治療の重要性はますます高まっている。本書は肺高血圧症を最初に診察する実地医家の先生方に、できるだけ早期に診断し、治療することの重要性を理解していただきたいと考え、企画されたものである。肺高血圧症の病態・診断・治療について、本症の専門家が「Q&A」形式でわかりやすく解説している。すべての実地医家の診療机に置いておきたい一冊。

目次

  • 肺高血圧症Q&A

    ―目次―

    Part 1　肺高血圧症治療の現状と疫学的背景をみる
    　Q1. 肺高血圧症とはどのような疾患なのでしょうか。
    　　　　最新の定義について教えてください。
    　Q2. 肺高血圧症にはどのような分類があるのでしょうか。
    　　　　また、それぞれどのくらいの頻度と予後でしょうか。

    Part 2　肺高血圧症の早期診断をめざす
    　Q3. 肺高血圧症の早期診断はなぜ必要なのでしょうか。
    　　　　治療介入のタイミングが予後に及ぼす影響について
    　　　　教えてください。
    　Q4. 肺高血圧症の診断はどのようにおこなうのでしょうか。
    　　　　診断アルゴリズム、専門医紹介のタイミングについて
    　　　　教えてください。
    　Q5. 肺高血圧症の早期診断のためにはどのような問診や身体所見
    　　　　に着目すべきでしょうか。
    　　　　肺高血圧症を疑うべきポイントについて教えてください。
    　…など9項目

    Part 3　肺高血圧症の病態をみる
    　Q12. 特発性肺動脈性肺高血圧症（IPAH）および遺伝性肺動脈性
    　　　　肺高血圧症（HPAH）の病態、治療指針の概略と予後に
    　　　　ついて教えてください。
    　Q13. 膠原病に伴う肺動脈性肺高血圧症の病態、
    　　　　治療指針と予後について教えてください。
    　Q14. IgG4 関連疾患、キャッスルマン病、高安動脈炎に伴う肺高
    　　　　血圧症の病態、治療指針と予後について教えてください。
    　…など11項目

    Part 4　肺高血圧症の治療戦略を探る
    　Q23. 肺高血圧症と診断された場合、ニース分類や日本および
    　　　　世界のガイドラインを踏まえ、どのような治療アルゴ
    　　　　リズムが提唱されているのでしょうか。
    　Q24. 肺高血圧症患者の日常生活指導のポイントと、
    　　　　QOLを低下させないための工夫を教えてください。
    　Q25. 成人患者に対するプロスタサイクリン製剤の在宅持続静注
    　　　　療法の実際、管理のコツについて教えてください。
    　…など22項目

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1 肺高血圧症治療の現状と疫学的背景をみる

P.23 掲載の参考文献
1) Higenbottam T, Wheeldon D, Wells F et al:Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol(prostacyclin). Lancet 1:1046-1047, 1984
PubMed
2) Rubin LJ, Mendoza J, Hood M et al:Treatment of primary pulmonary hypertension with continuous intrave-nous prostacyclin(epoprostenol). Results of a randomized trial. Ann Intern Med 112:485-491, 1990
 
3) McLaughlin VV, Genthner DE, Panella MM et al:Reduction in pulmonary vascular resistance with long-term epoprostenol(prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338:273-277, 1998
PubMed
4) Sasayama S, Kunieda T, Tomoike H et al:Effects of the endothelin receptor antagonist bosentan on hemody-namics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. Circ J 69:131-137, 2005
 
5) Galie N, Ghofrani HA, Torbicki A et al:Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148-2157, 2005
PubMed
6) 笹本浩:慢性肺性心. 新内科学大系35-A循環器疾患VIa, 中山書店, 東京, 277-306, 1978
 
7) Ed. by. Hatano S, Strasser T:Report on a WHO Meeting, Geneva, 15-17 October 1973, World Health Organiza-tion, Geneva, 1975
 
8) Badesch DB, Champion HC, Sanchez MA et al:Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54(1 Suppl):S55-S66, 2009
 
9) Ghofrani HA, Seeger W, Grimminger F:Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353:1412-1413, 2005
PubMed
10) Romberg E:Uber Sklerose der Lungenarterie. Dtsch Archiv Klin Med 48:197-206, 1891
 
11) Dresdale DT, Schultz M, Michtom RJ:Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med 11:686-705, 1951
PubMed
12) Voelkel NF:Drug-induced pulmonary hypertension:must history repeat itself? Pulm Pharmacol 9:67-68, 1996
PubMed
13) 国枝武義:肺高血圧症治療の展望. 週刊日本医事新報3362号:3-10, 1988
 
14) 国枝武義:正常気圧下における肺循環調節とその異常. 血管と内皮 9:493-500, 1999
 
P.28 掲載の参考文献
1) Simonneau G, Gatzoulis MA, Adatia I et al:Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34-D41, 2013
 
2) Galie N, Hoeper MM, Humbert M et al:Guidelines for the diagnosis and treatment of pulmonary hyperten-sion:the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC) and the European Respiratory Society(ERS), endorsed by the International Society of Heart and Lung Transplantation(ISHLT). Eur Heart J 30:2493-2537, 2009
 
3) Hurdman J, Condliffe R, Elliot CA et al:ASPIRE registry:assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 39:945-955, 2012
 
4) Rich S, Dantzker DR, Ayres SM et al:Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107:216-223, 1987
PubMed
5) 吉田俊治, 深谷修作:膠原病性肺高血圧症の頻度と病態の解析. 厚生労働科学研究費補助金免疫アレルギー疾患予防・治療研究事業 全身性自己免疫疾患における難治性病態の診断と治療法に関する研究班平成15年度総括・分担研究報告書:40-43, 2004
 
6) Kawut SM, Krowka MJ, Trotter JF et al:Clinical risk factors for portopulmonary hypertension. Hepatology 48:196-203, 2008
PubMed

Part 2 肺高血圧症の早期診断をめざす

P.34 掲載の参考文献
1) D'Alonzo GE, Barst RJ, Ayres SM et al:Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115:343-349, 1991
PubMed
2) Benza RL, Miller DP, Barst RJ et al:An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 142:448-456, 2012
PubMed
3) Benza RL, Miller DP, Gomberg-Maitland M et al:Predicting survival in pulmonary arterial hypertension:insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Man-agement(REVEAL). Circulation 122:164-172, 2010
 
4) Rubin LJ, Badesch DB, Fleming TR et al:Long-term treatment with sildenafil citrate in pulmonary arterial hypertension:the SUPER-2 study. Chest 140:1274-1283, 2011
PubMed
5) Galie N, Ghofrani HA, Torbicki A et al:Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148-2157, 2005
PubMed
6) Sanchez O, Sitbon O, Jais X et al:Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 130:182-189, 2006
PubMed
P.39 掲載の参考文献
1) Hoeper MM, Bogaard HJ, Condliffe R et al:Definitions and diagnosis of pulmonary hypertension.J Am Coll Cardiol 62(25 Suppl):D42-D50, 2013
 
P.44 掲載の参考文献
1) 国枝武義:「肺高血圧症の概念, 病態, 治療体制の確立に向けて」基調講演. Ther Res 26:2012-2021, 2005
Medical*Online
2) 高久史麿, 箕輪良行, 竹田津文俊(翻訳):ミシガン診察診断マニュアル, メディカル・サイエンス・インターナショナル, 東京, 1999
 
3) Constant J:Bedside Cardiology Fifth Edition, Lippincot Williams & Wilkins, Philadelphia, 1999
 
P.49 掲載の参考文献
1) Galie N, Hoeper MM, Humbert M et al:Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34:1219-1263, 2009
PubMed
2) 合同研究班(班長:中西宣文):循環器病の診断と診療に関するガイドライン(2011年度合同研究班報告)肺高血圧症治療ガイドライン(2012年改訂版), 2012
 
3) Foris V, Kovacs G, Tscherner M et al:Biomarkers in pulmonary hypertension:what do we know? Chest 144:274-283, 2013
PubMed
4) Nagaya N, Nishikimi T, Uematsu M et al:Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:865-870, 2000
PubMed
5) Benza RL, Miller DP, Gomberg-Maitland M et al:Predicting survival in pulmonary arterial hypertension:insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Man-agement(REVEAL). Circulation 122:164-172, 2010
 
6) Nagaya N, Uematsu M, Satoh T et al:Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 160:487-492, 1999
PubMed
7) Jinnin M, Ihn H, Yamane K et al:Plasma plasmin-alpha2-plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension. Rheumatology(Oxford) 42:240-243, 2003
PubMed
8) Sakamaki F, Kyotani S, Nagaya N et al:Increase in thrombomodulin concentrations after pulmonary thrombo-endarterectomy in chronic thromboembolic pulmonary hypertension. Chest 124:1305-1311, 2003
 
9) Quarck R, Nawrot T, Meyns B et al:C-reactive protein:a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 53:1211-1218, 2009
PubMed
10) Hampole CV, Mehrotra AK, Thenappan T et al:Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. Am J Cardiol 104:868-872, 2009
PubMed
11) Cella G, Vianello F, Cozzi F et al:Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmorlary hypertension related to connective tissue diseases. J Rheumatol 36:760-767, 2009
PubMed
12) Naito A, Tanabe N, Jujo T et al:Pentraxin3 in chronic thromboembolic pulmonary hypertension:a new bio-marker for screening from remitted pulmonary thromboembolism. PLoS One 9:e113086, 2014
 
13) Soon E, Holmes AM Treacy CM et al:Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation l22:920-927, 2010
 
14) Selimovic N, Bergh CH, Andersson B et al:Growth factors and interleukin-6 across the lung circulation in pulmorlary hypertension. Eur Respir J 34:662-668, 2009
PubMed
15) Lorenzen JM, Nickel N, Kramer R et al:Osteopontin in patients with idiopathic pulmonary hypertension. Chest 139:1010-1017, 2011
PubMed
16) Nickel N, Jonigk D, Kempf T et al:GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells. Respir Res 12:62, 2011
PubMed
17) Giaid A, Saleh D:Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333:214-221, 1995
PubMed
18) Rubens C, Ewert R, Halank M et al:Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120:1562-1569, 2001
PubMed
19) Kim J, Kang Y, Kojima Y et al:An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med 19:74-82, 2013
 
20) Skoro-Sajer N, Mittermayer F, Panzenboeck A et al:Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 176:1154-1160, 2007
PubMed
21) Kumpers P, Nickel N, Lukasz A et al:Circulating angiopoietins in idiopathic pulmonary arterial hypertension. Eur Heart J 31:2291-2300, 2010
PubMed
22) Bull TM, Golpon H, Hebbel RP et al:Circulating endothelial cells in pulmonary hypertension. Thromb Haemost 90:698-703, 2003
PubMed
23) Smadja DM, Gaussem P, Mauge L et al:Circulating endothelial cells:a new candidate biomarker of irrevers-ible pulmonary hypertension secondary to congenital heart disease. Circulation 119:374-381, 2009
 
24) Toshner M, Voswinckel R, Southwood M et al:Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med 180:780-787, 2009
PubMed
25) Junhui Z, Xingxiang W, Guosheng F et al:Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension. Respir Med 102:1073-1079, 2008
PubMed
P.54 掲載の参考文献
1) 合同研究班(班長:中西宣文):循環器病の診断と診療に関するガイドライン(2011年度合同研究班報告)肺高血圧症治療ガイドライン(2012年改訂版), 2012
 
2) Ng CS, Wells AU, Padley SP:A CT sign of chronic pulmonary arterial hypertension:the ratio of main pulmo-nary artery to aortic diameter.J Thorac Imaging 14:270-278, 1999
 
3) Revel MP, Faivre JB, Remy-Jardin M et al:Pulmonary hypertension:ECG-gated 64-section CT angiographic evaluation of new functional parameters as diagnostic criteria. Radiology 250:558-566, 2009
PubMed
4) 井上征雄, 谷本伸弘, 佐藤徹ほか:肺高血圧症のCT所見(特に原発性肺高血圧症と慢性肺血栓塞栓症の鑑別を中心に). 日本呼吸器学会雑誌 44:485-491, 2006
Medical*Online
5) Miura A, Akagi S, Nakamura K et al:Different sizes of centrilobular ground-glass opacities in chest high-resolution computed tomography of patients with pulmonary veno-occlusive disease and patients with pulmo-nary capillary hemangiomatosis. Cardiovasc Pathol 22:287-293, 2013
 
6) Moua T, Levin DL, Carmona EM et al:Frequency of mediastinal lymphadenopathy in patients with idiopathic pulmonary arterial hypertension. Chest 143:344-348, 2013
PubMed
7) Kramer CM, Barkhausen J, Flamm SD et al:Standardized cardiovascular magnetic resonance(CMR) proto-cols 2013 update.J Cardiovasc Magn Reson 15:91, 2013
 
8) Hundley WG, Bluemke D, Bogaert JG et al:Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn Reson 11:5, 2009
PubMed
9) Ley S, Fink C, Puderbach M et al:MRI measurement of the hemodynamics of the pulmonary and systemic arterial circulation:influence of breathing maneuvers. AJR Am J Roentgenol 187:439-444, 2006
PubMed
10) Johansson B, Babu-Narayan SV, Kilner PJ:The effects of breath-holding on pulmonary regurgitation mea-sured by cardiovascular magnetic resonance velocity mapping. J Cardiovasc Magn Reson 11:1, 2009
 
11) Oyama-Manabe N, Sato T, Tsujino I et al:The strain-encoded(SENC) MR imaging for detection of global right ventricular dysfunction in pulmonary hypertension. Int J Cardiovasc Imaging 29:371-378, 2013
PubMed
P.65 掲載の参考文献
1) McLaughlin VV, Archer SL, Badesch DB et al:ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians;American Thoracic Society, Inc. ;and the Pulmonary Hypertension Association. J Am Coll Cardiol 53:1573-1619, 2009
 
2) Galie N, Hoeper MM, Humbert M et al:Guidelines for the diagnosis and treatment of pulmonary hyperten-sion:the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC) and the European Respiratory Society(ERS), endorsed by the International Society of Heart and Lung Transplantation(ISHLT). Eur Heart J 30:2493-2537, 2009
 
3) Humbert M, Sitbon O, Chaouat A et al:Pulmonary arterial hypertension in France:results from a national registry. Am J Respir Crit Care Med 173:1023-1030, 2006
 
4) Hachulla E, Gressin V, Guillevin L et al:Early detection of pulmonary arterial hypertension in systemic scle-rosis:a French nationwide prospective multicenter study. Arthritis Rheum 52:3792-3800, 2005
 
5) Condliffe R, Kiely DG, Peacock AJ et al:Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179:151-157, 2009
PubMed
6) Naeije R, Vanderpool R Dhakal BP et al:Exercise-induced pulmonary hypertension:physiological basis and methodological concerns. Am J Respir Crit Care Med 187:576-583, 2013
PubMed
7) Maron BA, Cockrill BA, Waxman AB et al:The invasive cardiopulmonary exercise test. Circulation 127:1157-1164, 2013
PubMed
8) Rudski LG, Lai WW, Afilalo J et al:Guidelines for the echocardiographic assessment of the right heart in adults:a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 23:685-713, 2010
 
9) Bossone E, D'Andrea A, D'Alto M et al:Echocardiography in pulmonary arterial hypertension:from diagnosis to prognosis. J Am Soc Echocardiogr 26:1-14, 2013
 
10) Janda S, Shahidi N, Gin K et al:Diagnostic accuracy of echocardiography for pulmonary hypertension:a sys-tematic review and meta-analysis. Heart 97:612-622, 2011
 
11) 合同研究班(班長:中西宣文):循環器病の診断と診療に関するガイドライン(2011年度合同研究班報告)肺高血圧症治療ガイドライン(2012年改訂版), 2012
 
12) Lam CS, Roger VL, Rodeheffer RJ et al:Pulmonary hypertension in heart failure with preserved ejection frac-tion:a community-based study. J Am Coll Cardiol 53:1119-1126, 2009
 
13) Lang RM, Badano LP, Mor-Avi V et al:Recommendations for cardiac chamber quantification by echocardiog-raphy in adults:an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28:1-39, 2015
 
P.69 掲載の参考文献
1) D'Alonzo GE, Barst RJ, Ayres SM et al:Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115:343-349, 1991
PubMed
2) Kovacs G, Avian A, Olschewski A et al:Zero reference level for right heart catheterisation. Eur. Respir J 42:1586-1594, 2013
PubMed
3) Hoeper MM, Bogaard HJ, Condliffe R et al:Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D42-D50, 2013
 
4) Nakayama Y, Nakanishi N, Hayashi T et al:Pulmonary artery reflection for differentially diagnosing primary pulmonary hypertension and chronic pulmonary thromboembolism. J Am Coll Cardiol 38:214-218, 2001
PubMed
P.74 掲載の参考文献
1) Hoeper MM, Bogaard HJ, Condliffe R et al:Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D42-D50, 2013
 
2) Reichelt A, Hoeper MM, Galanski M et al:Chronic thromboembolic pulmonary hypertension:evaluation with 64-detector row CT versus digital substraction angiography. Eur J Radiol 71:49-54, 2009
PubMed
3) He J, Fang W, Lv B et al:Diagnosis of chronic thromboembolic pulmonary hypertension:comparison of ven-tilation/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography. Nucl Med Commun 33:459-463, 2012
 
4) Hoeper MM, Lee SH, Voswinckel R et al:Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 48:2546-2552, 2006
PubMed
5) Sugiyama M, Fukuda T, Sanda Y et al:Organized thrombus in pulmonary arteries in patients with chronic thromboembolic pulmonary hypertension;imaging with cone beam computed tomography. Jpn J Radiol 32:375-382, 2014
PubMed
P.78 掲載の参考文献
1) Barst RJ, McGoon M, Torbicki A et al:Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43(12 SupPl S):40S-47S, 2004
 
2) 合同研究班(班長:中西宣文):循環器病の診断と診療に関するガイドライン(2011年度合同研究班報告)肺高血圧症治療ガイドライン(2012年改訂版), 2012
 
3) Galie N, Hoeper MM, Humbert M et al:Guidelines for the diagnosis and treatment of pulmonary hyperten-sion:the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC) and the European Respiratory Society(ERS), endorsed by the International Society of Heart and Lung Transplantation(ISHLT). Eur Heart J 30:2493-2537, 2009
 
4) Sitbon O, Humbert M, Nunes H et al:Long-term intravenous epoprostenol infusion in primary pulmonary hypertension:prognostic factors and survival. J Am Coll Cardiol 40:780-788, 2002
PubMed
5) Ogawa A, Ejiri K Matsubara H:Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci 118:414-419, 2014
 
6) Yamaki S, Kumate M, Yonesaka S et al:Lung biopsy diagnosis of operative indication in secundum atrial sep-tal defect with severe pulmonary vascular disease. Chest 126:1042-1047, 2004
 
7) Yamaki S:Pulmonary vascular disease associated with pulmonary hypertension in 445 patients:diagnosis from lung biopsy and autopsy. Gen Thorac Cardiovasc Surg 61:24-31, 2013
PubMed
8) Yamaki S, Ando M, Fukumoto Y et al:Histopathological examination by lung biopsy for the evaluation of oper-ability and postoperative prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 78:476-482, 2014
 

Part 3 肺高血圧症の病態をみる

P.86 掲載の参考文献
1) 合同研究班(班長:中西宣文):循環器病の診断と診療に関するガイドライン(2011年度合同研究班報告)肺高血圧症治療ガイドライン(2012年改訂版), 2012
 
2) Ogawa A, Ejiri K, Matsubara H:Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci 118:414-419, 2014
 
P.91 掲載の参考文献
1) Simonneau G, Gatzoulis MA, Adatia I et al:Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34-D41, 2013
 
2) Benza RL, Miller DP, Barst RJ et al:An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 142:448-456, 2012
PubMed
3) Chung L, Liu J, Parsons L et al:Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL:identifying systemic sclerosis as a unique phenotype. Chest 138:1383-1394, 2010
PubMed
4) Launay D, Sitbon O, Le Pavec J et al:Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology(Oxford) 49:490-500, 2010
 
5) Condliffe R, Kiely DG, Peacock AJ et al:Connective tissue disease-associated pulmonary arteriai hypertension in the modern treatment era. Am J Respir Crit Care Med 179:151-157, 2009
 
6) Denton CP, Humbert M, Rubin L et al:Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease:a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 65:1336-1340, 2006
PubMed
7) Badesch DB, Hill NS, Burgess G et al:Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 34:2417-2422, 2007
PubMed
8) Humbert M, Yaici A, de Groote P et al:Screening for pulmonary arterial hypertension in patients with systemic sclerosis:clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 63:3522-3530, 2011
PubMed
9) 川口鎮司:膠原病性肺高血圧症. 治療学 44:857-860, 2010
Medical*Online
10) Tanaka E, Harigai M, Tanaka M et al:Pulmonary hypertension in systemic lupus erythematosus:evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 29:282-287, 2002
PubMed
11) Jais X, Launay D, Yaici A et al:Immunosuppressive therapy in lupus-and mixed connective tissue disease-associated pulmonary arterial hypertension:a retrospective analysis of twenty-three cases. Arthritis Rheum 58:521-531, 2008
PubMed
P.95 掲載の参考文献
1) Mikulicz-Radecki J:Uber eine eigenartige symmetrische Erkrankung der Thranen-und Mundspeicheldrusen. In:Czerny V, editor. Beitrage zur Chirurgie, Festschrift gewidmet Theodor Billroth, Stuttgart, 610-630, 1892
 
2) Morgan WS, Castleman B:A clinicopathologic study of Mikulicz's disease. Am J Pathol 29:471-503, 1953
PubMed
3) Hamano H, Kawa S, Horiuchi A et al:High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344:732-738, 2001
PubMed
4) Umehara H, Okazaki K, Masaki Y et al:A novel clinical entity, IgG4-related disease(IgG4RD):general con-cept and details. Mod Rheumatol 22:1-14, 2012
 
5) Deshpande V, Zen Y, Chan JK et al:Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25:1181-1192, 2012
PubMed
6) Shirai Y, Tamura Y, Yasuoka H et al:IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment. Eur Respir J 43:1516-1519, 2014
PubMed
7) Castleman B, Towne VW:Case records of the Massachusetts General Hospital:Case No.40231. N Engl J Med 250:1001-1005, 1954
PubMed
8) Keller AR, Hochholzer L, Castleman B:Hyaline-vascular and plasma-cell types of giant lymph node hyperpla-sia of the mediastinum and other locations. Cancer 29:670-683, 1972
 
9) Lin O, Frizzera G:Angiomyoid and follicular dendritic cell proliferative lesions in Castleman's disease of hya-line-vascular type:a study of 10 cases. Am J Surg Pathol 21:1295-1306, 1997
 
10) Furuya Y, Satoh T, Kuwana M:Interleukin-6 as a potential therapeutic target for pulmonary arterial hyper-tension. Int J Rheumatol 2010:720305, 2010
 
11) Soubrier M, Dubost JJ, Serre AF et al:Growth factors in POEMS syndrome:evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum 40:786-787, 1997
PubMed
12) Cohen T, Nahari D, Cerem LW et al:Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271 :736-741, 1996
PubMed
13) Allam JS, Kennedy CC, Aksamit TR et al:Pulmonary manifestations in patients with POEMS syndrome:a retrospective review of 137 patients. Chest 133:969-974, 2008
PubMed
14) Li J, Tian Z, Zheng HY et al:Pulmonary hypertension in POEMS syndrome. Haematologica 98:393-398, 2013
 
15) Takayasu M:A case with peculiar changes of the central retinal vessels. Acta Soc Ophthalmol Jpn 12:554-555, 1908
 
16) Yang L, Zhang H, Jiang X et al:Clinical manifestations and longterm outcome for patients with Takayasu arteritis in China. J Rheumatol 41:2439-2446, 2014
 
17) Wang X, Dang A, Chen B et al:Takayasu arteritis-associated pulmonary hypertension. J Rheumatol 42:495-503, 2015
PubMed
18) Yamada I, Shibuya H, Matsubara O et al:Pulmonary artery disease in Takayasu's arteritis:angiographic find-ings. AJR Am J Roentgenol 159:263-269, 1992
 
19) Yamato M, Lecky JW, Hiramatsu K et al:Takayasu arteritis:radiographic and angiographic findings in 59 patients. Radiology 161:329-334, 1986
PubMed
20) Arnaud L, Haroche J, Limal N et al:Takayasu arteritis in France:a single-center retrospective study of 82 cases comparing white, North African, and black patients. Medicine(Baltimore) 89:1-17, 2010
 
21) Lupi E, Sanchez G, Horwitz S et al:Pulmonary artery involvement in Takayasu's arteritis. Chest 67:69-74, 1975
PubMed
22) Sharma S, Kamalakar T, Rajani M et al:The incidence and patterns of pulmonary artery involvement in Takayasu's arteritis. Clin Radiol 42:177-181, 1990
PubMed
23) Lie JT:Isolated pulmonary Takayasu arteritis:clinicopathologic characteristics. Mod Pathol 9:469-474, 1996
PubMed
P.103 掲載の参考文献
1) Panos RJ, Baker SK:Mediators, cytokines, and growth factors in liver-lung interactions. Clin Chest Med 17:151-169, 1996
PubMed
2) Kuo PC, Plotkin JS, Johnson LB et al:Distinctive clinical features of portopulmonary hypertension. Chest 112:980-986, 1997
PubMed
3) McDonnell PJ, Toye PA, Hutchins GM:Primary pulmonary hypertension and cirrhosis:are they related? Am Rev Respir Dis 127:437-441, 1983
PubMed
4) Hadengue A, Benhayoun MK, Lebrec D et al:Pulmonary hypertension complicating portal hypertension:prevalence and relation to splanchnic hemodynamics. Gastroenterology 100:520-528, 1991
PubMed
5) Simonneau G, Gatzoulis MA, Adatia I et al:Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34-D41, 2013
 
6) Ramsay MA, Simpson BR, Nguyen AT et al:Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 3:494-500, 1997
PubMed
7) Benza RL, Miller DP, Gomberg-Maitland M et al:Predicting survival in pulmonary arterial hypertension:insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Man-agement(REVEAL). Circulation 122:164-172, 2010
 
8) McLaughlin VV, Genthner DE, Panella MM et al:Compassionate use of continuous prostacyclin in the manage-ment of secondary pulmonary hypertension:a case series. Ann Intern Med 130:740-743, 1999
 
9) Krowka MJ, Frantz RP, McGoon MD et al:Improvement in pulmonary hemodynamics during intravenous epoprostenol(prostacyclin):A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 30:641-648, 1999
PubMed
10) Plotkin JS, Kuo PC, Rubin LJ et al:Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Traransplantation 65:457-459, 1998
PubMed
11) Awdish RL, Cajigas HR:Early initiation of prostacyclin in portopulmonary hypertension:10 years of a trans-plant center's experience. Lung 191:593-600, 2013
 
12) Savale L, Magnier R, Le Pavec J et al:Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J 41:96-103, 2013
PubMed
13) Hoeper MM, Seyfarth HJ, Hoeffken G et al:Experience with inhaled iloprost and bosentan in portopullnonary hypertension. Eur Respir J 30:1096-1102, 2007
PubMed
14) Cartin-Ceba R, Swanson K, Iyer V et al:Safety and efficacy of ambrisentan for the treatment of portopulmo-nary hypertension. Chest 139:109-114, 2011
 
15) Pulido T, Adzerikho I, Channick RN et al:Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809-818, 2013
PubMed
16) Reichenberger F, Voswinckel R, Steveling E et al:Sildenafil treatment for portopulmonary hypertension. Eur Respir J 28:563-567, 2006
PubMed
17) Melgosa MT, Ricci GL, Garcia-Pagan JC et al:Acute and long-term effects of inhaled iloprost in portopulmo-nary hypertension. Liver Transpl 16:348-356, 2010
 
18) Krowka MJ, Plevak DJ, Findlay JY et al:Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 6:443-450, 2000
PubMed
19) Raevens S, Geerts A, Van Steenkiste C et al:Hepatopulmonary syndrome and portopulmonary hypertension:recent knowledge in pathogenesis and overview of clinical assessment. Liver Int 35:1646-1660, 2015
PubMed
20) Le Pavec J, Souza R, Herve P et al:Portopulmonary hypertension:survival and prognostic factors. Am J Respir Crit Care Med 178:637-643, 2008
PubMed
21) Swanson KL, Wiesner RH, Nyberg SL et al:Survival in portopulmonary hypertension:Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 8:2445-2453, 2008
 
P.109 掲載の参考文献
1) Shiina Y, Toyoda T, Kawasoe Y et al:Prevalence of adult patients with congenital heart disease in Japan. Int J Cardiol 146:13-16, 2011
PubMed
2) Lowe BS, Therrien J, Ionescu-Ittu R et al:Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 58:538-546, 2011
PubMed
3) van Riel AC, Schuuring MJ, van Hessen ID et al:Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol 174:299-305, 2014
PubMed
4) Simonneau G, Gatzoulis MA, Adatia I et al:Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34-D41, 2013
 
5) Alonso-Gonzalez R, Lopez-Guarch CJ, Subirana-Domenech MT et al:Pulmonary hyperterlsion and congenital heart disease:An insight from the REHAP National Registry. Int J Cardiol 184:717-723, 2015
 
6) Manes A, Palazzini M, Leci E et al:Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease:a comparison between clinical subgroups. Eur Heart J 35:716-724, 2014
PubMed
7) Barst RJ, Ivy DD, Foreman AJ et al:Four-and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension(from the REVEAL Registry). Am J Cardiol 113:147-155, 2014
PubMed
8) Akagi S, Ogawa A, Miyaji K et al:Catecholamine support at the initiation of epoprostenol therapy in pulmonary arterial hypertension. Ann Am Thorac Soc 11:719-727, 2014
PubMed
9) Ogawa A, Ejiri K, Matsubara H:Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci 118:414-419, 2014
 
10) Beghetti M, Galie N, Bonnet D:Can "inoperable" congenital heart defects become operable in patients with pulmonary arterial hypertension? Dream or reality? Congenit Heart Dis 7:3-11, 2012
PubMed
11) Tahara N, Mizoguchi M, Honda A et al:Successful shunt closure and improvement of hemodynamics in an ASD patient with severe pulmonary arterial hypertension and small shunt following a long-term use of bosentan. Int J Cardiol 158:e38-e40, 2012
 
12) Myers PO, Tissot C, Beghetti M:Assessment of operability of patients with pulmonary arterial hypertension associated with congenital heart disease. Circ J 78:4-11, 2014
PubMed
13) Galie N, Beghetti M, Gatzoulis MA et al:Bosentan therapy in patients with Eisenmenger syndrome:a multi-center, double-blind, randomized, placebo-controlled study. Circulation 114:48-54, 2006
 
14) Zhang ZN, Jiang X, Zhang R et al:Oral sildenafil treatment for Eisenmenger syndrome:a prospective, open-label, multicentre study. Heart 97:1876-1881, 2011
PubMed
15) Dimopoulos K, Inuzuka R, Goletto S et al:Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 121:20-25, 2010
PubMed
16) Baumgartner H, Bonhoeffer P, De Groot NM et al:ESC Guidelines for the management of grown-up congeni-tal heart disease(new version 2010). Eur Heart J 31:2915-2957, 2010
 
17) Iversen K, Jensen AS, Jensen TV et al:Combination therapy with bosentan and sildenafil in Eisenmenger syndrome:a randomized, placebo-controlled, double-blinded trial. Eur Heart J 31:1124-1131, 2010
PubMed
P.113 掲載の参考文献
1) Simonneau G, Gatzoulis MA, Adatia I et al:Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34-D41, 2013
 
2) Mandel J, Mark EJ, Hales CA:Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 162:1964-1973, 2000
PubMed
3) Eyries M, Montani D, Girerd B et al:EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 46:65-69, 2014
PubMed
4) Best DH, Sumner KL, Austin ED et al:EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest 145:231-236, 2014
PubMed
5) Pietra GG, Capron F, Stewart S et al:Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43(12 Suppl S):25S-32S, 2004
 
6) 循環器病の診断と治療に関するガイドライン. 肺高血圧症治療ガイドライン(2012年改訂版) http://www.j-circ.orjp/guideline/pdf/JCS2012_nakanishLh.pdf.
 
7) Ogawa A, Miyaji K, Yamadori I et al:Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Circ J 76:1729-1736, 2012
PubMed
8) Overbeek MJ, van Nieuw Amerongen GP, Boonstra A et al:Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J 32:232-235, 2008
PubMed
9) Adachi S, Hirashiki A, Kondo T et al:Imatinib is partially effective for the treatment of pulmonary capillary hemangiomatosis. Intern Med 53:603-607, 2014
PubMed
10) Almagro P, Julia J, Sanjaume M et al:Pulmonary capillary hemangiomatosis associated with primary pulmo-nary hypertension:report of 2 new cases and review of 35 cases from the literature. Medicine(Baltimore) 81:417-424, 2002
 
P.114 掲載の参考文献
1) Momma K, Linde LM, Goldberg SJ et al:Effects of cardiac glycosides on the abnormal pulmonary circulation of the dog. Am Heart J 79:80-87, 1970
PubMed
2) Momma K, Linde LM, Fonkalsrud EW et al:Hemodynamics and blood gas exchange in allografted canine lungs. I. Immediate effects. Surgery 67:799-806, 1970
 
3) 門間和夫, 高尾篤良, 三森重和:肺高血圧を伴う心室中隔欠損症の自然歴. 心臓 4:452-460, 1972
 
4) 門間和夫, 高尾篤良:心室中隔欠損症における肺血管閉塞性病変の頻度と進行性. 心臓 6, 1411-1417, 1974
 
P.118 掲載の参考文献
1) Vachiery JL, Adir Y, Barbera JA et al:Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 62(25 Suppl):D100-D108, 2013
 
2) Prasad A, Hastings JL, Shibata S et al:Characterization of static and dynamic left ventricular diastolic function in patients with heart failure with a preserved ejection fraction. Circ Heart Fail 3:617-626, 2010
PubMed
3) Robbins IM, Hemnes AR, Pugh ME et al:High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 7:116-122, 2014
PubMed
4) Robbins IM, Newman JH, Johnson RF et al:Association of the metabolic syndrome with pulmonary venous hypertension. Chest 136:31-36, 2009
PubMed
5) Fox BD, Shimony A, Langleben D et al:High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J 42:1083-1091, 2013
PubMed
6) Borlaug BA, Nishimura RA, Sorajja P et al:Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 3:588-595, 2010
PubMed
7) Naeije R, Vachiery JL, Yerly P et al:The transpulmonary pressure gradierlt for the diagnosis of pulmonary vascular disease. Eur Respir J 41:217-223, 2013
PubMed
8) Gerges C, Gerges M, Lang MB et al:Diastolic pulmonary vascular pressure gradient:a predictor of prognosis in "out-of-proportion" pulmonary hypertension. Chest 143:758-766, 2013
PubMed
9) Tedford RJ, Beaty CA, Mathai SC et al:Prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. J Heart Lung Transplant 33:289-297, 2014
PubMed
10) Tampakakis E, Leary PJ, Selby VN et al:The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail 3:9-16, 2015
 
11) Gaynor SL, Maniar HS, Bloch JB et al:Right atrial and ventricular adaptation to chronic right ventricular pres-sure overload. Circulation 112(9 Suppl):I212-I218, 2005
 
12) Lewis GD, Lachmann J, Camuso J et al:Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115:59-66, 2007
PubMed
13) Guazzi M, Samaja M, Arena R et al:Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 50:2136-2144, 2007
PubMed
14) Guazzi M, Vicenzi M, Arena R et al:Pulmonary hypertension in heart failure with preserved ejection fraction:a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124:164-174, 2011
 
P.124 掲載の参考文献
1) Simonneau G, Gatzoulis MA, Adatia I et al:Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34-D41, 2013
 
2) Fishman AP:Pulmonary hypertension and cor pulmonale, In:Fishman's Pulmonary Diseases and Disorders 3rd edition. ed. by Fishman, AP. et al. , Mcgraw-Hill, New York, 1998, pp.1261-1296
 
3) 石橋正義, 吉田稔:肺性心:1. 概念と発生機序. 日本内科学会雑誌 82:789-793, 1993
 
4) 岡田修, 栗山喬之:3. 低酸素性肺血管収縮. 日本内科学会雑誌 82:799-804, 1993
 
5) 坂巻文雄:(6)肺高血圧症と呼吸不全. 血管医学 8:269-276, 2007
Medical*Online
6) Migueres M, Escamilla R, Coca F et al:Pulsed Doppler echocardiography in the diagnosis of pulmonary hyper-tension in COPD. Chest 98:280-285, 1990
 
7) Nagaya N, Nishikimi T, Uematsu M et al:Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:865-870, 2000
PubMed
8) 合同研究班(班長:中西宣文):3. 肺疾患および/または低酸素血症による肺高血圧症. 循環器病の診断と診療に関するガイドライン(2011年度合同研究班報告)肺高血圧症治療ガイドライン(2012年改訂版), 42-50, 2013
 
9) Hurdman J, Condliffe R, Elliot CA et al:ASPIRE registry:assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 39:945-955, 2012
 
10) Olschewski H, Ghofrani HA, Walmrath D et al:Inhaled prostacyclin and iloprost in severe pulmonary hyperten-sion secondary to lung fibrosis. Am J Respir Crit Care Med 160:600-607, 1999
 
11) Ghofrani HA, Osterloh IH, Grimminger F:Sildenafil:from angina to erectile dysfunction to pulmonary hyper-tension and beyond. Nat Rev Drug Discov 5:689-702, 2006
 
12) Ghofrani HA, Wiedemann R, Rose F et al:Sildenafil for treatment of lung fibrosis and pulmonary hyperten-sion:a randomised controlled trial. Lancet 360:895-900, 2002
 
13) King TE Jr, Brown KK, Raghu G et al:BUILD-3:a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184:92-99, 2011
PubMed
14) Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M et al:A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 363:620-628, 2010
 
15) Raghu G, Behr J, Brown KK et al:Treatment of idiopathic pulmonary fibrosis with ambrisentan:a parallel, randomized trial. Ann Intern Med 158:641-649, 2013
PubMed
16) Chaouat A, Bugnet AS, Kadaoui N et al:Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172:189-194, 2005
PubMed
17) Tanabe N, Taniguchi H, Tsujino I et al:Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. Respirology:20:805-812, 2015
PubMed
18) Seeger W, Adir Y, Barbera JA et al:Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 62(25Suppl):D109-D116, 2013
 
P.129 掲載の参考文献
1) Moser KM, Auger WR Fedullo PF:Chronic major-vessel thromboembolic pulmonary hypertension. Circula-tion 81:1735-1743, 1990
 
2) Pengo V, Lensing AW, Prins MH et al:Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257-2264, 2004
PubMed
3) Kominami S, Tanabe N, Ota M et al:HLA-DPB1 and NFKBIL1 may confer the susceptibility to chronic throm-boembolic pulmonary hypertension in the absence of deep vein thrombosis. J Hum Genet 54:108-114, 2009
 
4) Morris TA, Marsh JJ, Chiles PG et al:Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 173:1270-1275, 2006
PubMed
5) Maruoka M, Sakao S, Kantake M et al:Characterization of myofibroblasts in chronic thromboembolic pulmo-nary hypertension. Int J Cardiol 159:119-127, 2012
 
6) Nishimura R, Tanabe N, Sugiura T et al:Improved survival in medically treated chronic thromboembolic pul-monary hypertension. Circ J 77:2110-2117, 2013
 
7) 田邉信宏, 笠原靖紀, 巽浩一郎ほか:臨床調査個人票からみた日本における慢性血栓塞栓性肺高血圧症の診断, 治療現況に関する研究. 厚生労働科学研究費補助金難治性疾患克服研究事業 呼吸不全に関する調査研究平成23年度研究報告書:249-253, 2012
 
8) 合同研究班(班長:中西宣文):循環器病の診断と診療に関するガイドライン(2011年度合同研究班報告)肺高血圧症治療ガイドライン(2012年改訂版), 2012
 
9) 合同研究班(主査:伊藤浩):2011-2013年度合同研究班報告2014年版慢性肺動脈血栓塞栓症に対するballoon pulmonary angioplastyの適応と実施法に関するステートメント, 2014
 
10) Ghofrani HA, D'Armini AM, Grimminger F et al:Riociguat for the treatment of chronic thromboembolic pul-monary hypertension. N Engl J Med 369:319-329, 2013
 
11) Kim NH, Delcroix M, Jenkins DP et al:Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D92-D99, 2013
 
12) Lang IM, Madani M:Update on chronic thromboembolic pulmonary hypertension. Circulation 130:508-51&2014
 
13) Riedel M, Stanek V, Widimsky J et al:Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 81:151-158, 1982
PubMed
14) Yoshimi S, Tanabe N, Masuda M et al:Survival and quality of life for patients with peripheral type chronic thromboembolic pulmonary hypertension. Circ J 72:958-965, 2008
PubMed
15) Condliffe R, Kiely DG, Gibbs JS et al:Improved outcomes in medically and surgically treated chronic thrombo-embolic pulmonary hypertension. Am J Respir Crit Care Med 177:1122-1127, 2008
 
16) Nishimura R, Tanabe N, Sugiura T et al:Improved survival in medically treated chronic thromboembolic pul-monary hypertension. Circ J 77:2110-2117, 2013
 
P.135 掲載の参考文献
1) Humbert M, Lau EM, Montani D et al:Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 130:2189-2208, 2014
PubMed
2) Humpl T, Schultz-Neick I:Pulmonary Vascular Disease. ed. by Anderson RH, Baker EJ, Redington A et al:Paediatric Cardiology 3rd ed. Churchill, Livingstone, Elsevior. 1147-1161, 2009
 
3) Saji T, Momma K, Shibata T et al:National survey of idiopathic pulmonary arterial hypertension. Ped Cardol Card Surg 16:230-237, 2000
 
4) Ichida F, Saji T, Kajino H et al:Annual report of the national survey of cardiovascular rare diseases. Ped Cardol Card Surg 26:348-350, 2010
 
5) Loyd JE, Atkinson JB, Pietra GG et al:Heterogeneity of pathologic lesions in familial primary pulmonary hyper-tension. Am Rev Respir Dis 138:952-957, 1988
 
6) Barst RJ:Primary Pulmonary Hypertension in Children. ed. by Rubin LJ, Rich S:Lung Biology in Health and Disease, Marcel Dekker Inc. NY. 99:179-225, 1997
 
7) Moride Y, Abenhaim L, Xu J:Epidemiology of pulmonary hypertension in primary pulmonary hypertension. ed. by Rubin LJ, Rich S, editors:Primary Pulmonary HyPertension, Marcel Dekker Inc. NY. 163-178, 1997
 
8) Fujiwara M, Yagi H, Matsuoka R et al:Implications of mutations of activin receptor-like kinase 1 gene(ALK1) in addition to bone morphogenetic protein receptor II gene(BMPR2)in children with pulmonary arterial hypertension. Circ J 72:127-133, 2008
PubMed
9) Harrison RE, Flanagan JA, Sankelo M et al:Molecular and functional analysis identifies ALK-1 as the pre-dominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 40:865-871, 2003
 
10) Shintani M, Yagi H, Nakayama T et al:A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet 46:331-337, 2009
 
11) Chida A, Shintani M, Nakayama T et al:Missense mutations of the BMPR1B(ALK6) gene in childhood idio-pathic pulmonary arterial hypertension. Circ J 76:1501-1508, 2012
 
12) Shimodaira K, Okubo Y, Ochiai E et al:Gene expression analysis of a murine model with pulmonary vascular remodeling compared to end-stage IPAH lungs. Respir Res 103:13, 2012
PubMed
13) Yuan K, Orcholski ME, Panaroni C et al:Activation of the Wnt/planar cell polarity pathway is required for pericyte recruitment during pulmonary angiogenesis. Am J Pathol 185:69-84, 2015
PubMed
14) Cool CD, Rai PR, Yeager ME et al:Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 349:1113-1122, 2003
PubMed
15) Yeager ME, Nguyen CM, Belchenko DD et al:Circulating myeloid-derived suppressor cells are increased and activated in pulmonary hypertension. Chest 141:944-952, 2012
PubMed
16) Smadja DM, Mauge L, Gaussem P et al:Treprostinil increases the number and angiogenic potential of endo-thelial progenitor cells in children with pulmonary hypertension. Angiogenesis 14:17-27, 2011
 
17) Roberts KE, McElroy JJ, Wong WP et al:BMPR2 mutations in pulmonary arterial hypertension with con-genital heart disease. Eur Respir J 24:371-374, 2004
 
18) Grunig E, Koehler R, Miltenberger-Miltenyi G et al:Primary pulmonary hypertension in children may have a different genetic background than in adults. Pediatr Res 56:571-578, 2004
PubMed
19) Harrison RE, Berger R, Haworth SG et al:Transforming growth factor-beta receptor mutations and pulmo-nary arterial hypertension in childhood. Circulation 111:435-441, 2005
 
20) Austin ED, Loyd JE:Genetics and mediators in pulmonary arterial hypertension. Clin Chest Med 28:43-57, 2007
PubMed
21) Rosenzweig EB, Morse JH, Knowles JA et al:Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung TransPlant 27:668-674, 2008
 
22) Chida A, Shintani M, Yagi H et al:Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALKI mutation carriers. Am J Cardiol 110:586-593, 2012
 
23) Lee A, McLean D, Choi J et al:Therapeutic implications of microRNAs in pulmonary arterial hypertension. BMB Rep 47:311-317, 2014
PubMed
24) Bienertova-Vasku J, Novak J, Vasku A:MicroRNAs in pulmonary arterial hypertension:pathogenesis, diag-nosis and treatment. J Am Soc Hypertens 9:221-234, 2015
 
25) Sutendra G, Michelakis ED:The metabolic basis of pulmonary arterial hypertension. Cell Metab 19:558-573, 2014
 
26) Nakayama T, Shimada H, Takatsuki S et al:Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children. Circ J 71:1785-1790, 2007
PubMed
27) Takatsuki S, Wagner BD, Ivy DD et al:B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. Congenit Heart Dis 7:259-267, 2012
 
28) Barst RJ, Ertel SI, Beghetti M et al:Pulmonary arterial hypertension:a comparison between children and adults. Eur Respir J 37:665-677, 2011
PubMed
29) Barst RJ, Maislin G, Fishman AP:Vasodilator therapy for primary pulmonary hypertension in children. Circu-lation 99:1197-1208, 1999
 
30) Lammers AE, Hislop AA, Flynn Y et al:Epoprostenol treatment in children with severe pulmonary hyperten-sion. Heart 93:739-743, 2007
 
31) Galie N, Hoeper MM, Humbert M et al:Guidelines for the diagnosis and treatment of pulmonary hyperten-sion:the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC) and the European Respiratory Society(ERS), endorsed by the International Society of Heart and Lung Transplantation(ISHLT). Eur Heart J 30:2493-2537, 2009
 
32) McLaughlin VV, Archer SL, Badesch DB et al:ACCF/AHA 2009 expert consensus document on pulmonary hypertension:a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association:developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc. , and the Pulmonary Hypertension Association. Circulation 119:2250-2294, 2009
 
33) 合同研究班(班長:中西宣文):循環器病の診断と診療に関するガイドライン(2011年度合同研究班報告)肺高血圧症治療ガイドライン(2012年改訂版), 2012
 
34) Roman A, Barbera JA, Escribano P et al:Cost effectiveness of prostacyclins in pulmonary arterial hyperten-sion. Appl Health Econ Health Policy 10:175-188, 2012
 
35) Satoh M, Aso K Nakayama T et al:Autoimmune thyroid disease in children and adolescents with idiopathic pulmonary arterial hypertension. Circ J 74:371-374, 2010
PubMed
36) Ivy DD, Saji B:Medical management of severe pediatric pulmonary arterial hypertension. Pediatric Pulmonary Hypertension:Beghetti M, Barst RJ, Berger RMF et al. Elsevier:315-328, 2011
 
37) Siehr SL, Ivy DD, Miller-Reed K et al:Children with pulmonary arterial hypertension and prostanoid ther-apy:long-term hemodynamics. J Heart Lung Transplant 32:546-552, 2013
 
38) McLaughlin VV, Genthner DE, Panella MM et al:Reduction in pulmonary vascular resistance with long-term epoprostenol(prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338:273-277, 1998
PubMed
39) McLaughlin VV, Shillington A, Rich S:Survival in primary pulmonary hypertension:the impact of epopros-tenol therapy. Circulation 106:1477-1482, 2002
PubMed
40) Sitbon O, Humbert M, Simonneau G et al:Primary pulmonary hypertension:Current therapy. Prog Cardiovasc Dis 45:115-128, 2002
PubMed
41) 佐地勉, 山田修, 中山智孝ほか:小児期肺動脈性肺高血圧症症例におけるエポプロステノール治療の有効性と安全性の長期検討-市販後使用成績調査からの検討. 心臓 40:34-43, 2008
Medical*Online
42) 中山智孝, 嶋田博光, 高月晋一ほか:総説:小児肺動脈性肺高血圧症におけるフローラン投与開始後の治療の現状. Prog Med 25:325-329, 2005
Medical*Online
43) 岡田博, 高田充隆, 森下秀樹ほか:小児におけるエポプロステノール(PGI2)持続静注療法時の投与量の検討. Jpn. J. Pharm. Health Care Sci. 32:805-812, 2006
 
44) 大谷秀雄, 京谷晋吾, 二藤部丈司ほか:フローランの増量法, 導入後の投与量設定について. Prog Med 25:306-310, 2005
 
45) Siehr SL, Ivy DD, Milier-Reed K et al:Children with pulmonary arterial hypertension and prostanoid ther-apy:long-term hemodynamics. J Heart Lung Transplant 32:546-552, 2013
 
46) Melnick L, Barst RJ, Rowan CA et al:Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension. Am J Cardiol 105:1485-1489, 2010
PubMed
47) Ploegstra MJ, Zijlstra WM, Douwes JM et al:Prognostic factors in pediatric pulmonary arterial hypertension:A systematic review and meta-analysis. Int J Cardiol 184:198-207, 2015
PubMed
48) Yung D, Widlitz AC, Rosenzweig EB et al:Outcomes in children with idiopathic pulmonary arterial hyperten-sion. Circulation 110:660-665, 2004
 
49) Saji T:Update on pediatric pulmonary arterial hypertension. Differences and similarities to adult disease. Circ J 77:2639-2650, 2013
PubMed
P.141 掲載の参考文献
1) Simonneau G, Gatzoulis MA, Adatia I et al:Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34-D41, 2013
 
2) Simonneau G, Robbins IM, Beghetti M et al:Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54(1 Suppl):S43-S54, 2009
 
3) Lahm T, Chakinala MM:World Health Organization group 5 pulmonary hypertension. Clin Chest Med 34:753-778, 2013
PubMed
4) Hurdman J, Condliffe R, Elliot CA et al:ASPIRE registry:assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 39:945-955, 2012
 
5) Klings ES, Machado RF, Barst RJ et al:An official American Thoracic Society clinical practice guideline:diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med 189:727-740, 2014
PubMed
6) Nunes H, Humbert M, Capron F et al:Pulmonary hypertension associated with sarcoidosis:mechanisms, haemodynamics and prognosis. Thorax 61:68-74, 2006
PubMed
7) Dobarro D, Schreiber BE, Handler C et al:Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. Am J Cardiol 111:278-285, 2013
 
8) Baughman RP, Culver DA, Cordova FC et al:Bosentan for sarcoidosis-associated pulmonary hypertension:a double-blind placebo controlled randomized trial. Chest 145:810-817, 2014
PubMed
9) Sise ME, Courtwright AM, Channick RN:Pulmonary hypertension in patients with chronic and end-stage kidney disease. Kidney Int 84:682-692, 2013
PubMed
10) Yigla M, Fruchter O, Aharonson D et al:Pulmonary hypertension is an independent predictor of mortality in hemodialysis patients. Kidney Int 75:969-975, 2009
PubMed

Part 4 肺高血圧症の治療戦略を探る

P.148 掲載の参考文献
1) Ed. by Simonneau G, Galie N:Updates in pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl), A1-8, D1-128, 2013
 
P.152 掲載の参考文献
1) 合同研究班(班長:松崎益徳):循環器病の診断と治療に関するガイドライン(2009年度合同研究班報告)慢性心不全治療ガイドライン(2010年改訂版), 2010
 
2) Belardinelli R, Georgiou D, Cianci G et al:Exercise training improves left ventricular diastolic filling in patients with dilated cardiomyopathy. Clinical and prognostic implications. Circulation 91:2775-2784, 1995
PubMed
3) シェルドン・コーエンほか(編著), 小杉正太郎ほか(監訳):ソーシャルサポートの測定と介入, 川島書店, 東京, 2005
 
4) American Lung Association:Understanding PAH. [http://www.lung.org/lung-disease/pulmonary-arteriai-hypertension/understanding-pah.html]
 
5) Badesch DB, Raskob GE, Elliott CG et al:Pulmonary arterial hypertension:baseline characteristics from the REVEAL Registry. Chest 137:376-387, 2010
PubMed
6) Brown LM, Chen H, Halpern S et al:Delay in recognition of pulmonary arterial hypertension:factors identified from the REVEAL Registry. Chest 140:19-26, 2011
 
P.162 掲載の参考文献
1) Taichman DB, Ornelas J, Chung L et al:Pharmacologic therapy for pulmonary arterial hypertension in adults:CHEST guideline and expert panel report. Chest 146:449-475, 2014
 
2) Galie N, Corris PA, Frost A et al:Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62(25 Suppl):D60-D72, 2013
 
3) Ivy DD, Abman SH, Barst RJ et al:Pediatric pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D117-126, 2013
 
4) 福島裕之:特発性肺動脈性肺高血圧症. 小児内科 45:1104-1106, 2013
Medical*Online
5) 福島裕之:医療現場における子どもと家族への疾患・治療の説明, 心理的準備. 小児看護 36:625-629, 2013
 
P.167 掲載の参考文献
1) White RJ, Levin Y, Wessman K et al:Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics. Pulm Circ 3:611-621, 2013
PubMed
2) Rich JD, Glassner C, Wade M et al:The effect of diluent pH on bloodstream infection rates in patients receiv-ing IV treprostinil for pulmonary arterial hypertension. Chest 141:36-42, 2012
 
3) Bergot E, Sitbon O, Cottin V et al:Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension:data from the French pulmonary hypertension regis-try. Int J Cardiol 172:561-567, 2014
PubMed
4) 合同研究班(班長:中西宣文):循環器病の診断と診療に関するガイドライン(2011年度合同研究班報告)肺高血圧症治療ガイドライン(2012年改訂版), 2012
 
5) Channick RN, Frantz RP, Kawut SM et al:A multicenter, retrospective study of patients with pulmonary arte-rial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost. Pulm Circ 3:381-388, 2013
 
P.174 掲載の参考文献
1) Miyagawa K, Emoto N:Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Ther Adv Cardiovasc Dis 8:202-216, 2014
PubMed
2) Rubin LJ, Badesch DB, Barst RJ et al:Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896-903, 2002
PubMed
3) Galie N, Beghetti M, Gatzoulis MA et al:Bosentan therapy in patients with Eisenmenger syndrome:a multi-center, double-blind, randomized, placebo-controlled study. Circulation 114:48-54, 2006
 
4) Galie N, Rubin LJ, Hoeper M et al:Treatment of patients with mildly symptomatic pulmonary arterial hyper-tension with bosentan(EARLY study):a double-blind, randomised controlled trial. Lancet 371:2093-2100, 2008
 
5) Jais X, D'Armini AM, Jansa P et al:Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension:BENEFiT(Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 52:2127-2134, 2008
 
6) Galie N, Olschewski H, Oudiz RJ et al:Ambrisentan for the treatment of pulmonary arterial hypertension:results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy(ARIES) study 1 and 2. Circulation 117:3010-3019, 2008
PubMed
7) Badesch DB, Feldman J, Keogh A et al:ARIES-3:ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 30:93-99, 2012
 
8) Pulido T, Adzerikho I, Channick RN et al:Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809-818, 2013
PubMed
9) Ghofrani HA, Galie N, Grimminger F et al:Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330-340, 2013
PubMed
P.179 掲載の参考文献
1) Archer SL, Michelakis ED:Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 361 :1864-1871, 2009
PubMed
2) Giaid A, Saleh D:Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmo-nary hypertension. N Engl J Med 333:214-221, 1995
 
3) Black SM, Sanchez LS, Mata-Greenwood E et al:sGC and PDE5 are elevated in lambs with increased pulmo-nary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 281:L1051-LlO57, 2001
 
4) Murray F, MacLean MR, Pyne NJ:Increased expression of the cGMP-inhibited cAMP-specific(PDE3)and cGMP binding cGMP-specific(PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 137:1187-1194, 2002
PubMed
5) Nagendran J, Archer SL, Soliman D et al:Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116:238-248, 2007
PubMed
6) Michelakis ED, Wilkins MR, Rabinovitch M:Emerging concepts and translational priorities in pulmonary arte-rial hypertension. Circulation 118:1486-1495, 2008
 
7) Wharton J, Strange JW, Moller GM et al:Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172:105-113, 2005
PubMed
8) Remillard CV, Yuan JX:Activation of K+ channels:an essential pathway in programmed cell death. Am J Physiol Lung Cell Mol Physiol 286:L49-L67, 2004
PubMed
9) Budhiraja R, Tuder RM, Hassoun PM:Endothelial dysfunction in pulmonary hypertension. Circulation 109:159-165, 2004
PubMed
10) Watanabe H:Inhibition of type-5 phosphodiesterase:promising therapy for pulmonary hypertension. Intern Med 43:891-893, 2004
PubMed
11) Galie N, Ghofrani HA, Torbicki A et al:Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148-2157, 2005
PubMed
12) Galie N, Brundage BH, Ghofrani HA et al:Tadalafil therapy for pulmonary arterial hypertension. Circulation 119:2894-2903, 2009
PubMed
13) 合同研究班(班長:中西宣文):循環器病の診断と診療に関するガイドライン(2011年度合同研究班報告)肺高血圧症治療ガイドライン(2012年改訂版), 2012
 
14) Rubin LJ, Badesch DB, Fleming TR et al:Long-term treatment with sildenafil citrate in pulmonary arterial hypertension:the SUPER-2 study. Chest 140:1274-1283, 2011
PubMed
P.184 掲載の参考文献
1) Humbert M, Sitbon O, Simonneau G:Treatment of pulmonary arterial hypertension. N Engl Med 351:1425-1436, 2004
PubMed
2) Giaid A, Saleh D:Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmo-nary hypertension. N Engl J Med 333:214-221, 1995
 
3) Schermuly RT, Janssen W, Weissmann N et al:Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs 20:567-576, 2011
PubMed
4) Bice JS, Burley DS, Baxter GF:Novel approaches and opportunities for cardioprotective signaling through 3', 5'-cyclic guanosine monophosphate manipulation. J Cardiovasc Pharmacol Ther 19:269-282, 2014
 
5) Stasch JP, Hobbs AJ:NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 191:277-308, 2009
PubMed
6) Lang M, Kojonazarov B, Tian X et al:The soiuble guanylate cyclase stimulator riociguat ameliorates pulmo-nary hypertension induced by hypoxia and SU5416 in rats. PLoS One 7:e43433, 2012
 
7) Chester M, Seedorf G, Tourneux P et al:Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 301:L755-L764, 2011
PubMed
8) Erdmann E, Semigran MJ, Nieminen MS et al:Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J 34:57-67, 2013
PubMed
9) Glynos C, Dupont LL, Vassilakopoulos T et al:The role of soluble guanylyl cyclase in chronic obstructive pul-monary disease. Am J Respir Crit Care Med 188:789-799, 2013
 
10) Weissmann N, Lobo B, Pichl A et al:Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. Am J Respir Crit Care Med 189:1359-1373, 2014
PubMed
11) Ghofrani HA, D'Armini AM, Grimminger F et al:Riociguat for the treatment of chronic thromboembolic pul-monary hypertension. N Engl J Med 369:319-329, 2013
 
12) Ghofrani HA, Galie N, Grimminger F et al:Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330-340, 2013
PubMed
13) Simonneau G, D'Armini AM, Ghofrani HA et al:Riociguat for the treatment of chronic thromboembolic pulmo-nary hypertension:a long-term extension study(CHEST-2). Eur Respir J 45:1293-1302, 2015
 
14) Rubin LJ, Galie N, Grimminger F et al:Riociguat for the treatment of pulmonary arterial hypertension:a long-term extension study(PATENT-2). Eur Respir J 45:1303-1313, 2015
PubMed
15) Sugimura K, Fukumoto Y, Satoh K et al:Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 76:485-488, 2012
PubMed
16) Mizoguchi H, Ogawa A, Munemasa M et al:Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc lnterv 5:748-755, 2012
PubMed
17) Kataoka M, Inami T, Hayashida K et al:Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 5:756-762, 2012
PubMed
18) Updates in Pulmonary Hypertension(ed. by. , Simonneau G, Galie N):J Am Coll Cardiol 62(25 Suppl):A1-A8, D1-D128, 2013
 
19) Galie N, Muller K, Scalise AV et al:PATENT PLUS:a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J 45:1314-1322, 2015
 
20) Bonderman D, Ghio S, Felix SB et al:Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction:a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemody-namic study. Circulation 128:502-511, 2013
 
21) Bonderman D, Pretsch I, Steringer-Mascherbauer R et al:Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure(DILATE-1):a randomized, double-blind, placebo-controlled, single-dose study. Chest 146:1274-1285, 2014
PubMed
22) Hoeper MM, Halank M, Wilkens H et al:Riociguat for interstitial lung disease and pulmonary hypertension:a pilot trial. Eur Respir J 41:853-860, 2013
PubMed
23) Pieske B, Butler J, Filippatos G et al:Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies(SOCRATES). Eur J Heart Fail 16:1026-1038, 2014
PubMed
P.192 掲載の参考文献
1) Barst RJ:PDGF signaling in pulmonary arterial hypertension. J Clin Invest 115:2691-2694, 2005
PubMed
2) Heldin CH, Westermark B:Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316, 1999
PubMed
3) Humbert M, Monti G, Fartoukh M et al:Platelet-derived growth factor expression in primary puimonary hypertension:comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 11:554-559, 1998
 
4) Schermuly RT, Dony E, Ghofrani HA et al:Reversal of experimental pulmonary hypertension by PDGF inhibi-tion. J Clin Invest 115:2811-2821, 2005
 
5) Perros F, Montani D, Dorfmuller P et al:Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178:81-88, 2008
PubMed
6) Ghofrani HA, Seeger W, Grimminger F:Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353:1412-1413, 2005
PubMed
7) Hatano M, Yao A, Shiga T et al:Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J 51:272-276, 2010
PubMed
8) Ghofrani HA, Morrell NW, Hoeper MM et al:Imatinib in pulmonary arterial hypertension patients with inad-equate response to established therapy. Am J Respir Crit Care Med 182:1171-1177, 2010
 
9) Hoeper MM, Barst RJ, Bourge RC et al:Imatinib mesylate as add-on therapy for pulmonary arterial hyperten-sion:results of the randomized IMPRES study. Circulation 127:1128-1138, 2013
 
10) Gomberg-Maitland M, Maitland ML, Barst RJ et al:A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther 87:303-310, 2010
PubMed
11) Montani D, Bergot E, Gunther S et al:Pulmonary arterial hypertension in patients treated by dasatinib. Circu-lation 125:2128-2137, 2012
 
12) Tamura Y, Ono T, Sano M et al:Favorable effect of sorafenib in a patient with neurofibromatosis-associated pulmonary hypertension. Am J Respir Crit Care Med 186:291-292, 2012
 
P.196 掲載の参考文献
1) Reeves JT, Groves BM, Turkevich D:The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis 134:342-346, 1986
PubMed
2) Ogawa A, Ejiri K, Matsubara H:Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci 118:414-419, 2014
 
3) Shimokawa H, Takeshita A:Rho-kinase is an important therapeutic target in cardiovascular medicine. Arte-rioscler Thromb Vasc Biol 25:1767-1775, 2005
 
4) Kimura K, Ito M, Amano M et al:Regulation of myosin phosphatase by Rho and Rho-associated kinase(Rho-kinase). Science 273:245-248, 1996
PubMed
5) Sebbagh M, Renvoize C, Hamelin J et al:Caspase-3-mediated cleavage of ROCK I induces MLC phosphoryla-tion and apoptotic membrane blebbing. Nat Cell Biol 3:346-352, 2001
 
6) Satoh K, Fukumoto Y, Shimokawa H:Rho-kinase:important new therapeutic target in cardiovascular dis-eases. Am J Physiol Heart Circ Physiol 301:H287-H296, 2011
 
7) Sitbon O, Humbert M, Jais X et al:Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105-3111, 2005
PubMed
8) Do e Z, Fukumoto Y, Takaki A et al:Evidence for Rho-kinase activation in patients with pulnlonary arterial hypertension. Circ J 73:1731-1739, 2009
PubMed
9) Abe K, Shimokawa H, Morikawa K et al:Long-term treatment with a Rho-kinase inhibitor improves mono-crotaline-induced fatal pulmonary hypertension in rats. Circ Res 94:385-393, 2004
 
10) Shimizu T, Fukumoto Y, Tanaka S et al:Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice. Arterioscler Thromb Vasc Biol 33:2780-2791, 2013
PubMed
11) Fukumoto Y, Matoba T, Ito A et al:Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91:391-392, 2005
PubMed
12) Fujita H, Fukumoto Y, Saji K et al:Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 25:144-149, 2010
PubMed
13) Fukumoto Y, Yamada N, Matsubara H et al:Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J 77:2619-2625, 2013
PubMed
14) Toba M, Alzoubi A, O'Neill K et al:A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension. Am J Pathol 184:369-375, 2014
 
15) Chen L, Nakano K, Kimura S et al:Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension 57:343-350, 2011
PubMed
P.200 掲載の参考文献
1) Johnson SR, Mehta S, Granton JT:Anticoagulation in pulmonary arterial hypertension:a qualitative system-atic review. Eur Respir J 28:999-1004, 2006
 
2) Said K:Anticoagulation in pulmonary arterial hypertension:Contemporary data from COMPERA registry. Glob Cardiol Sci Pract 2014:48-52, 2014
PubMed
3) Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology(ESC);European Respiratory Society(ERS);International Society of Heart and Lung Transplantation(ISHLT), Galie N, Hoeper MM et al:Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34:1219-1263, 2009
 
4) Badesch DB, Abman SH, Simonneau G et al:Medical therapy for pulmonary arterial hypertension:updated ACCP evidence-based clinical practice guidelines. Chest 131:1917-1928, 2007
PubMed
5) 合同研究班(班長:中西宣文):循環器病の診断と診療に関するガイドライン(2011年度合同研究班報告)肺高血圧症治療ガイドライン(2012年改訂版), 2012
 
6) Ogawa A, Matsubara H, Fujio H et al:Risk of alveolar hemorrhage in patients with primary pulmonary hyper-tension--anticoagulation and epoprostenol therapy. Circ J 69:216-220, 2005
 
7) Olsson KM, Delcroix M, Ghofrani HA et al:Anticoagulation and survival in pulmonary arterial hypertension:results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hyperten-sion(COMPERA). Circulation 129:57-65, 2014
 
P.205 掲載の参考文献
1) Yao A:Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension. J Cardiol 60:344-349, 2012
PubMed
2) Raghu G, Behr J, Brown KK et al:Treatment of idiopathic pulmonary fibrosis with ambrisentan:aparallel, randomized trial. Ann Intern Med 158:641-649, 2013
 
3) Foresta C, Caretta N, Zuccarello D et al:Expression of the PDE5 enzyme on human retinal tissue:new aspects of PDE5 inhibitors ocular side effects. Eye(Lond) 22:144-149, 2008
PubMed
4) Laties AM:Vision disorders and phosphodiesterase type 5 inhibitors:a review of the evidence to date. Drug Saf 32:1-18, 2009
PubMed
5) Fraunfelder FW, Fraunfelder FT:Central serous chorioretinopathy associated with sildenafil. Retina 28:606-609, 2008
PubMed
6) Tripathi A, O'Donnell NP:Branch retinal artery occlusion;another complication of sildenafil. Br J Ophthalmol 84:934-935, 2000
PubMed
7) Wirostko BM, Tressler C, Hwang LJ et al:Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension:results from phase III, randomised, double masked, placebo controlled trial and open label extension. BMJ 344:e554, 2012
PubMed
8) Cordell WH, Maturi RK, Costigan TM et al:Retinal effects of 6 months of daily use of tadalafil or sildenafil. Arch Ophthalmol 127:367-373, 2009
PubMed
9) Khan AS, Sheikh Z, Khan S et al:Viagra deafness--sensorineural hearing loss and phosphodiesterase-5 inhibitors. Laryngoscope 121 :1049-1054, 2011
PubMed
10) Maddox PT, Saunders J, Chandrasekhar SS:Sudden hearing loss from PDE-5 inhibitors:A possible cellular stress etiology. Larygoscope 119:1586-1589, 2009
 
11) Chin KM, Channick RN, de Lemos JA et al:Hemodynamics and epoprostenol use are associated with throm-bocytopenia in pulmonary arterial hypertension. Chest 135:130-136, 2009
 
12) Akagi S, Ogawa A, Miyaji K et al:Catecholamine support at the initiation of epoprostenol therapy in pulmonary arterial hypertension. Ann Am Thorac Soc 11:719-727, 2014
PubMed
P.210 掲載の参考文献
1) Kawakami Y, Kishi F, Yamamoto H et al:Relation of oxygen delivery, mixed venous oxygenation, and pulmo-nary hemodynamics to prognosis in chronic obstructive pulmonary disease. N Engl J Med 308:1045-1049, 1983
 
2) Nagaya N, Uematsu M, Satoh T et al:Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 160:487-492, 1999
PubMed
3) Oya H, Nagaya N, Satoh T et al:Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome. Heart 84:53-58, 2000
PubMed
4) Foris V, Kovacs G, Tscherner M et al:Biomarkers in pulmonary hypertension:what do we know? Chest 144:274-283, 2013
PubMed
5) 厚生省特定疾患「呼吸不全」調査研究班, 昭和56年度研究業績, 1982
 
6) 厚生省保険局医療課, 厚生省老人保健福祉局老人保健課編:医科点数表の解釈-社会保険・老人保健診療報酬 平成6年4月版, 1994
 
P.214 掲載の参考文献
1) Rubin LJ:Primary pulmonary hypertension. N Engl J Med 336:111-117, 1997
PubMed
2) Rich S, Kaufmann E, Levy PS:The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76-81, 1992
PubMed
3) Galie N, Corris PA, Frost A et al:Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62(25 Suppl):D60-D72, 2013
 
4) Humbert M, Sitbon O, Chaouat A et al:Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122:156-163, 2010
PubMed
5) Galie N, Hoeper MM, Humbert M et al:Guidelines for the diagnosis and treatment of pulmonary hypertension:the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC) and the European Respiratory Society(ERS), endorsed by the International Society of Heart and Lung Transplantation(ISHLT). Eur Heart J 30:2493-2537, 2009
 
6) Simonneau G, Rubin LJ, Galie N et al:Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension:a randomized trial. Ann Intern Med 149:521-530, 2008
 
7) Humbert M, Barst RJ, Robbins IM et al:Combination of bosentan with epoprostenol in pulmonary arterial hypertension:BREATHE-2. Eur Respir J 24:353-359, 2004
PubMed
8) McLaughlin VV, Benza RL, Rubin LJ et al:Addition of inhaled treprostinil to oral therapy for pulmonary arte-rial hypertension:a randomized controlled clinical trial. J Am Coll Cardiol 55:1915-1922, 2010
 
9) Gruenig E, Michelakis E, Vachiery JL et al:Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension:results of the COMPASS-1 study. J Clin Pharmacol 49:1343-1352, 2009
PubMed
10) Burgess G, Hoogkamer H, Collings L et al:Mutual pharmacokinetic interactions between steady-state bosen-tan and sildenafil. Eur J Clin Pharmacol 64:43-50, 2008
 
11) Rubin LJ, Badesch DB, Fleming TR et al:Long-term treatment with sildenafil citrate in pulmonary arterial hypertension:the SUPER-2 study. Chest 140:1274-1283, 2011
PubMed
12) Kylhammar D, Persson L, Hesselstrand R et al:Prognosis and response to first-line single and combination therapy in pulrnonary arterial hypertension. Scand Cardiovasc J 48:223-233, 2014
PubMed
13) Sitbon O, Jais X, Savale L et al:Upfront triple combination therapy in pulmonary arterial hypertension:a pilot study. Eur Respir J 43:1691-1697, 2014
PubMed
14) McLaughlin VV, Shah SJ, Souza R et al:Management of Pulmonary Arterial Hypertension. J Am Coll Cardiol 65:1976-1997, 2015
PubMed
P.217 掲載の参考文献
1) Moncada S, Gryglewski R, Bunting S et al:An enzyme isolated from arteries transforms prostaglandin endoper-oxides to an unstable substance that inhibits platelet aggregation. Nature 263:663-665, 1976
 
2) Higenbottam T, Wheeldon D. Wells F et al:Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol(prostacyclin). Lancet 1:1046-1047, 1984
PubMed
3) Barst RJ, Rubin LJ, Long WA et al:A comparison of continuous intravenous epoprostenol(prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334:296-301, 1996
PubMed
4) 河合忠一, 国枝武義, 白土邦男ほか:4UA76(エポプロステノールナトリウム)の原発性肺高血圧症に対する臨床評価. 臨床医薬 12:33-63, 1995
 
P.222 掲載の参考文献
1) Vonk-Noordegraaf A, Haddad F, Chin KM et al:Right heart adaptation to pulmonary arterial hypertension:physiology and pathobiology. J Am Coll Cardiol 62(25 Suppl):D22-D33, 2013
 
2) Haddad F, Hunt SA, Rosenthal DN et al:Right ventricular function in cardiovascular disease, part I:Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 117:1436-1448, 2008
PubMed
3) Friedberg MK, Redington AN:Right versus left ventricular failure:differences, similarities, and interactions. Circulation 129:1033-1044, 2014
PubMed
4) Gugiin M, Verma S:Right side of heart failure. Heart Fail Rev 17:511-527, 2012
 
5) Bogaard HJ, Natarajan R, Henderson SC et al:Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 120:1951-1960, 2009
PubMed
6) Piao L, Fang YH, Parikh KS et al:GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy:therapeutic implications in pulmonary hypertension. Circulation 126:2859-2869, 2012
PubMed
7) Piao L, Fang YH, Cadete VJ et al:The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy:resuscitating the hibernating right ventricle. J Mol Med(Berl) 88:47-60, 2010
PubMed
8) Ryan JJ, Archer SL:The right ventricle in pulmonary arterial hypertension:disorders of metabolism, angio-genesis and adrenergic signaling in right ventricular failure. Circ Res 115:176-188, 2014
 
9) Alpert JS:The effect of right ventricular dysfunction on left ventricular form and function. Chest 119:1632-1633, 2001
PubMed
10) Gan C, Lankhaar JW, Marcus JT et al:Impaired left ventricular filling due to right-to-left ventricular interac-tion in patients with pulmonary arterial hypertension. Am Physiol Heart Circ Physiol 290:H1528-H1533, 2006
 
11) Barst RJ, Gibbs JS, Ghofrani HA et al:Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol54(1 Suppl):S78-S84, 2009
 
12) Ito M, Kodama M, Kashimura T et al:Comparison of patients with pulmonary arterial hypertension with ver-sus without right-sided mechanical alternans. Am J Cadiol 109:428-431, 2012
 
13) Wen L, Sun ML, An P et al:Frequency of supraventricular arrhythmias in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol 114:1420-1425, 2014
PubMed
14) Chadha C, Pritzker M, Mariash CN:Effect of epoprostenol on the thyroid gland:enlargement and secretion of thyroid hormone. Endocr Pract 15:116-121, 2009
PubMed
P.227 掲載の参考文献
1) Shirai Y, Yasuoka H, Okano Y et al:Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension:a single-centre cohort. Rheumatology(Oxford) 51:1846-1854, 2012
PubMed
2) Overbeek MJ, Vonk MC, Boonstra A et al:Pulmonary arterial hypertension in limited cutaneous systemic sclerosis:a distinctive vasculopathy. Eur Respir J 34:371-379, 2009
PubMed
3) Sanchez O, Sitbon O, Jais X et al:Immunosuppressive therapy in connective tissue diseases-associated pulmo-nary arterial hypertension. Chest 130:182-189, 2006
 
4) Jais X, Launay D, Yaici A et al:Immunosuppressive therapy in lupus-and mixed connective tissue disease-associated pulmonary arterial hypertension:a retrospective analysis of twenty-three cases. Arthritis Rheum 58:521-531, 2008
PubMed
5) Hurdman J, Condliffe R, Elliot CA et al:ASPIRE registry:assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 39:945-955, 2012
 
6) Chung L, Farber HW, Benza R et al:Unique predictors of mortality in patients with pulmonary arterial hyper-tension associated with systemic sclerosis in the REVEAL registry. Chest 146:1494-1504, 2014
 
P.232 掲載の参考文献
1) Reitz BA, Wallwork JL, Hunt SA et al:Heart-lung transplantation:successful therapy for patients with pul-monary vascular disease. N Engl J Med 306:557-564, 1982
 
2) Toronto Lung Transplant Group:Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med 314:1140-1145, 1986
 
3) Pasque MK, Trulock EP, Cooper JD et al:Single lung transplantation for pulmonary hypertension. Single insti-tution experience in 34 patients. Circulation 92:2252-2258, 1995
 
4) Pasque MK, Cooper JD, Kaiser LR et al:Improved technique for bilateral lung transplantation:rationale and initial clinical experience. Ann Thorac Surg 49:785-791, 1990
PubMed
5) Date H, Yamashita M, Nagahiro I et al:Living-donor lobar lung transplantation for primary ciliary dyskinesia. Ann Thorac Surg 71 :2008-2009, 2001
PubMed
6) Date H, Nagahiro I, Aoe M et al:Living-donor lobar lung transplantation for primary pulmonary hypertension in an adult. J Thorac Cardiovasc Surg 122:817-818, 2001
 
7) Weill D, Benden C, Corris PA et al:A consensus document for the selection of lung transplant candidates:2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 34:1-15, 2015
PubMed
8) Date H, Sato M, Aoyama A et al:Living-donor lobar lung transplantation provides similar survival to cadaveric lung transplantation even for very ill patients. Eur J Cardiothorac Surg 47:967-973, 2015
PubMed
9) Bando K, Armitage JM, Paradis IL et al:Indications for and results of single, bilateral, and heart-lung trans-plantation for pulmonary hypertension. J Thorac Cardiovasc Surg 108:1056-1065, 1994
 
10) Katz WE, Gasior TA, Quinlan JJ et al:Immediate effects of lung transplantation on right ventricular morphology and function in patients with variable degrees of pulmonary hypertension. J Am Coll Cardiol 27:384-391, 1996
PubMed
11) Mendeloff EN, Meyers BF, Sundt TM et al:Lung transplantation for pulmonary vascular disease. Ann Thorac Surg 73:209-217, 2002
PubMed
12) Waddell TK, Bennett L, Kennedy R et al:Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant 21:731-737, 2002
PubMed
13) Date H, Kusano KF, Matsubara H et al:Living-donor lobar lung transplantation for pulmonary arterial hyper-tension after failure of epoprostenol therapy. J Am Coll Cardiol 50:523-527, 2007
 
14) Aokage K Date H, Okazaki M et al:Living-donor lobar lung transplantation and closure of atrial septal defect for adult Eisenmenger's syndrome. J Heart Lung Transplant 28:1107-1109, 2009
PubMed
15) Chen F, Fujinaga T, Shoji T et al:Outcomes and pulmonary function in living lobar lung transplant donors. Transpl Int 25:153-157, 2012
PubMed
16) Bowdish ME, Barr ML, Schenkel FA et al:A decade of living lobar lung transplantation:perioperative com-plications after 253 donor lobectomies. Am J TransPlant 4:1283-1288, 2004
 
17) Sato M, Okada Y, Oto T et al:Registry of the Japanese Society of Lung and Heart-Lung Transplantation:official Japanese lung transplantation report, 2014. Gen Thorac Cardiovasc Surg 62:594-601, 2014
PubMed
18) Yusen RD, Edwards LB, Kucheryavaya AY et al:The registry of the International Society for Heart and Lung Transplantation:thirty-first adult lung and heart-lung transplant report--2014;focus theme:retransplantation. J Heart Lung Transplant 33:1009-1024, 2014
PubMed
P.237 掲載の参考文献
1) Lopes AA, O'Leary PW:Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease. Cardiol Young 19:431-435, 2009
 
P.241 掲載の参考文献
1) 合同研究班(班長:丹羽公一郎):循環器病の診断と治療に関するガイドライン(2010年度合同研究班報告)成人先天性心疾患診療ガイドライン(2011年改訂版), 2011
 
2) Shiina Y, Toyoda T, Kawasoe Y et al:Prevalence of adult patients with congenital heart disease in Japan. Int J Cardiol 146:13-16, 2011
PubMed
3) Engelfriet PM, Duffels MG, Moller T et al:Pulmonary arterial hypertension in adults born with a heart septal defect:the Euro Heart Survey on adult congenital heart disease. Heart 93:682-687, 2007
PubMed
4) Duffels MG, Engelfriet PM, Berger RM et al:Pulmonary arterial hypertension in congenital heart disease:an epidemiologic perspective from a Dutch registry. Int J Cardiol 120:198-204, 2007
PubMed
5) Lowe BS, Therrien J, Ionescu-Ittu R et al:Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Asrdiol 58:538-546, 2011
PubMed
6) Simonneau G, Gatzoulis MA, Adatia I et al:Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34-D41, 2013
 
P.246 掲載の参考文献
1) Jamieson SW, Auger WR, Fedullo PF et al:Experience and results with 150 pulmonary thromboendarterec-tomy operations over a 29-month period. J Thorac Cardiovasc Surg 106:116-126, 1993
 
2) Jamieson SW, Kapelanski DP, Sakakibara N et al:Pulmonary endarterectomy:experience and lessons learned in 1,500 cases. Ann Thorac Surg 76:1457-1462, 2003
PubMed
3) 合同研究班(班長:中西宣文):循環器病の診断と診療に関するガイドライン(2011年度合同研究班報告)肺高血圧症治療ガイドライン(2012年改訂版), 50-56, 2012
 
4) Kim NH, Delcroix M, Jenkins DP et al:Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D92-D99, 2014
 
5) Mizoguchi H, Ogawa A, Munemasa M et al:Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 5:748-755, 2012
PubMed
6) Mayer E, Jenkins D, Lindner J et al:Surgical management and outcome of patients with chronic thromboem-bolic pulmonary hypertension:results from an international prospective registry. J Thorac Cardiovasc Surg 141:702-710, 2011
 
7) Madani MM, Auger WR, Pretorius V et al:Pulmonary endarterectomy:recent changes in a single institution's experience of more than 2,700 patients. Ann Thorac Surg 94:97-103, 2012
 
8) Taboada D, Pepke-Zaba J, Jenkins DP et al:Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J 44:1635-1645, 2014
PubMed
9) Thistlethwaite PA, Mo M, Madani MM et al:Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. J Thorac Cardiovasc Surg 124:1203-1211, 2002
PubMed
10) Ogino H, Ando M, Matsuda H et al:Japanese single-center experience of surgery for chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 82:630-636, 2006
PubMed
11) Ishida K, Masuda M, Tanabe N et al:Long-term outcome after pulmonary endarterectomy for chronic throm-boembolic pulmonary hypertension. J Thorac Cardiovasc Surg 144:321-326, 2012
 
12) Freed DH, Thomson BM, Berman M et al:Survival after pulmonary thromboendarterectomy:effect of residual pulmonary hypertension. J Thorac Cardiovasc Surg 141:383-387, 2011
PubMed
P.252 掲載の参考文献
1) Feinstein JA, Goldhaber SZ, Lock JE et al:Balloon pulmonary angioplasty for treatment of chronic thrombo-embolic pulmonary hypertension. Circulation 103:10-13, 2001
 
2) Sugimura K, Fukumoto Y, Satoh K et al:Percutaneos transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hyperlension. Circ J 76:485-488, 2012
 
3) Mizoguchi H, Ogawa A, Munemasa M et al:Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 5:748-755, 2012
PubMed
4) Kataoka M, Inami T, Hayashida K et al:Percutaneous transluminal pulmonary angioplasty for the treaunent of chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv 5:756-762, 2012
PubMed
5) Andreassen AK, Ragnarsson A, Gude E et al:Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Heart 99:1415-1420, 2013
PubMed
6) Inami T, Kataoka M, Shimura N et al:Pulmonary edema predictive scoring index(PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous translumi-nal pulmonary angioplasty. JACC Cardiovasc Interv 6:725-736, 2013
 
7) Fukui S, Ogo T, Morita Y et al:Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J 43:1394-1402, 2014
PubMed
8) Taniguchi Y, Miyagawa K, Nakayama K et al:Balloon pulmonary angioplasty:an additional treatment option to improve the prognosis of patients with chronic thromboembolic pulmonary hypertension. EuroIntervention 10:518-525, 2014
PubMed
9) Yanagisawa R, Kataoka M, Inami T et al:Safety and efficacy of percutaneous transluminal pulmonary angio-plasty in elderly patients. Int J Cardiol 175:285-289, 2014
 
10) Inami T, Kataoka M, Ando M et al:A new era of therapeutic strategies for chronic thromboembolic pulmonary hypertension by two different interventional therapies;pulmonary endarterectomy and percutaneous translu-minal pulmonary angioplasty. PLoS One 9:e94587, 2014
 
11) Inami T, Kataoka M, Shimura N et al:Pressure-wire-guided percutaneous transluminal pulmonary angio-plasty:a breakthrough in catheter-interventional therapy for chronic thromboembolic pulmonary hyperten-sion. JACC Cardiovasc Interv 7:1297-1306, 2014
 
12) Tsugu T, Murata M, Kawakami T et al:Significance of echocardiographic assessment for right ventricular function after balloon pulmonary angioplasty in patients with chronic thromboembolic induced pulmonary hypertension. Am J Cardiol 115:256-261, 2015
PubMed
13) Kawakami T, Kataoka M, Nakahara T et al:Usefulness of 3D SPECT/CT fusion image in CTEPH. Int J Car-diol 194:39-40, 2015
 
14) Inohara T, Kawakami T, Kataoka M et al:Lesion morphological classification by OCT to predict therapeutic efficacy after balloon pulmonary angioplasty in CTEPH. Int J Cardiol 197:23-25, 2015
PubMed
P.257 掲載の参考文献
1) Working group on Cardiac Rehabilitation & Exercise Physiology and Working Group on Heart Failure of the European Society of Cardiology:Recommendations for exercise training in chronic heart failure patients. Eur Heart J 22:125-135, 2001
 
2) 西崎真里, 宮地克維, 松原広己:3)肺高血圧症患者における運動療法の効果とその可能性. PROGRESS IN MEDICINE 34:1449-1455, 2014
Medical*Online
3) Mereles D, Ehlken N, Kreuscher S et al:Exercise and respiratory training improve exercise capacity and qual-ity of life in patients with severe chronic pulmonary hypertension. Circulation 114:1482-1489, 2006
 
4) Mainguy V, Maltais F, Saey D et al:Peripheral muscle dysfunction in idiopathic pulmonary arterial hyperten-sion. Thorax 65:113-117, 2010
 
5) de Man FS, Handoko ML, Groepenhoff H et al:Effects of exercise training in patients with idiopathic pulmo-nary arterial hypertension. Eur Respir J 34:669-675, 2009
 
6) Peled N, Bendayan D, Shitrit D et al:Peripheral endothelial dysfunction in patients with pulmonary arterial hypertension. Respir Med 102:1791-1796, 2008
PubMed
7) Velez-Roa S, Ciarka A, Najem B et al:Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 110:1308-1312, 2004
PubMed
8) Linke A, Schoene N, Gielen S et al:Endo thelial dysfunction patients with chronic heart failure:systemic effects of lower-limb exercise training. J Am Coll Cardiol 37:392-397, 2001
 
9) Coats AJ, Adamopoulos S, Radaelli A et al:Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 85:2119-2131, 1992
PubMed

書評

最近チェックした商品履歴

Loading...